Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
41
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Ceres Power Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Solid Oxide Licensing Will Expand Global Reach
Key Takeaways Ceres Power's licensing business model and strategic partnerships facilitate global market expansion and revenue growth, despite trade wars and economic pressures. Innovation in solid oxide technology and effective cost management enhance competitive edge, attract partnerships, and support a profitable, self-sustaining business model.
View narrative
UK£1.65
FV
32.0% undervalued
intrinsic discount
6.76%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
26
users have followed this narrative
1 day ago
author updated this narrative
Peach Property Group
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Stefanie Koch And Refinancing Will Improve Operational Efficiency
Key Takeaways Operational efficiency gains and strategic focus on reducing vacancy rates are anticipated to boost net margins and earnings. Financial restructuring through asset sales and debt reduction strengthens financial position and supports potential revenue growth.
View narrative
CHF 7.77
FV
13.5% undervalued
intrinsic discount
-7.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
1 day ago
author updated this narrative
Codexis
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
ECO Platform Partnerships Will Transform Pharma Manufacturing
Key Takeaways ECO platform adoption and advanced enzyme technologies drive higher-margin, recurring revenues and strengthen Codexis's competitive position in pharma and biotechnology markets. Strategic partnerships and investment in GMP capabilities expand revenue diversification, customer retention, and earnings stability while supporting long-term margin and growth improvement.
View narrative
US$7.08
FV
57.5% undervalued
intrinsic discount
29.27%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
1 day ago
author updated this narrative
Nyxoah
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
FDA Approval Will Unlock New Sleep Market Opportunities
Key Takeaways Imminent U.S. approval and unique technology position Nyxoah for strong adoption and rapid revenue growth in a large, underserved market. Robust reimbursement channels, global expansion, and ongoing product innovation set the stage for sustained earnings growth and improved operating leverage.
View narrative
€12.80
FV
55.7% undervalued
intrinsic discount
195.19%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
1 day ago
author updated this narrative
ClearPoint Neuro
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Minimally Invasive Neurosurgery Will Improve Global Clinical Outcomes
Key Takeaways Expanding demand for advanced neurological treatments and partnerships with biopharma firms position ClearPoint for accelerated recurring revenue and margin growth. Investments in technology, global regulatory approvals, and hospital efficiency support higher market share, utilization, and reduced financial risk internationally.
View narrative
US$29.00
FV
60.2% undervalued
intrinsic discount
24.20%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
1 day ago
author updated this narrative
kneat.com
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Digital Validation Will Unlock Expansion In Regulated Industries
Key Takeaways Strong demand for digital validation in regulated industries, coupled with product enhancements, drives recurring revenue growth and expands margin potential amid rising regulatory complexity. Land-and-expand strategy, flexible platform, and broader vertical reach deepen customer relationships, support price resilience, and fuel robust, visible future growth.
View narrative
CA$7.90
FV
29.5% undervalued
intrinsic discount
29.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
1 day ago
author updated this narrative
CVRx
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
CPT Code Change Will Expand Heart Failure Treatment Adoption
Key Takeaways Upcoming reimbursement improvements and expanded clinical evidence are set to boost physician adoption, leading to higher procedure volumes and increased revenue leverage. Strategic sales force expansion and targeted education will drive sustained demand, better market penetration, and enhanced long-term profitability.
View narrative
US$10.83
FV
35.1% undervalued
intrinsic discount
21.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
1 day ago
author updated this narrative
Alpha Teknova
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Automation And Biopharma Outsourcing Will Drive Market Expansion
Key Takeaways Ability to deliver custom, high-quality reagents and operational efficiency positions the company for market share gains and improved margins as industry demand increases. Diversified customer base and limited exposure to industry risks provide stability and support recurring revenue growth and account expansion.
View narrative
US$10.00
FV
53.1% undervalued
intrinsic discount
14.62%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
1 day ago
author updated this narrative
Spire Global
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
NASA And NOAA Partnerships Will Advance Space Services Amid Competition
Key Takeaways Expansion into real-time Earth observation and analytics, along with major government contracts, supports stable and recurring revenue growth across multiple verticals. Streamlined operations and new proprietary technologies improve product differentiation, enabling margin expansion and greater investment in long-term innovation.
View narrative
US$16.25
FV
43.9% undervalued
intrinsic discount
-4.37%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
1 day ago
author updated this narrative
Value any company in seconds
Popular companies